MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpet.2026.105012

Медицинская библиотека · The Journal of pharmacology and experimental therapeutics · 2026

Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed/refractory diffuse large B-cell lymphoma: An exploratory clinical study.

Huang Yunhong, Yang Yuan, Hu Yunfei, Tang Jingling, Liao Kai, Wu Liyun, Jiang Haiyan, Liu Honglin, Shen Jindan, Li Xiaoyang, Xue Yang, Wang Yuan, Yang Kunqiao, Gu Rongjie, Cheng Yuan

СтатьяПеревод в очереди

Аннотация

Natural killer (NK) cell dysfunction contributes to tumor resistance, particularly in antibody-dependent cell-mediated cytotoxicity. This study evaluated a fully chemically defined system for expanding high-purity NK (hpNK) cells and their clinical application. In preclinical studies, hpNK demonstrated strong antibody-dependent cell-mediated cytotoxicity activity in combination with rituximab. An exploratory clinical trial involving 19 patients with relapsed/refractory diffuse large B-cell lymphoma assessed the safety and preliminary clinical efficacy of combining allogeneic hpNK (shiheleucel) with anti-CD20 antibody and chemotherapy. Among 17 patients treated, no dose-limiting toxicity was observed. Among the 12 patients who underwent at least 1 postbaseline positron emission tomography and computed tomography efficacy assessment, the investigator-assessed objective response rate was 75.0% (9/12), including 7 complete responses and 2 partial responses. Median progression-free survival was 24 weeks, with median overall survival not reached at the time of analysis. Shiheleucel demonstrated a manageable safety profile and preliminary clinical activity, warranting further evaluation in larger controlled studies. SIGNIFICANCE STATEMENT: This study demonstrates that a fully chemically defined expansion system can generate high-purity natural killer (NK) cells with potent antibody-dependent cell-mediated cytotoxicity activity in preclinical settings. In an exploratory clinical trial combining allogeneic NK cell therapy with anti-CD20 antibody and chemotherapy to treat relapsed/refractory diffuse large B-cell lymphoma provided a manageable safety profile and evidence of clinical activity. These findings support further investigation of antibody-dependent cell-mediated cytotoxicity-driven NK cell-based allogeneic cell therapy.

Для цитирования: Huang Yunhong, Yang Yuan, Hu Yunfei, Tang Jingling, Liao Kai, Wu Liyun, Jiang Haiyan, Liu Honglin, Shen Jindan, Li Xiaoyang, Xue Yang, Wang Yuan, Yang Kunqiao, Gu Rongjie, Cheng Yuan. Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed/refractory diffuse large B-cell lymphoma: An exploratory clinical study.. The Journal of pharmacology and experimental therapeutics. 2026. DOI: 10.1016/j.jpet.2026.105012.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.